Evidence map›Paper›PMID 42153675›Full record

ArticleClinical and translational science2026

From Precision to Personalized: Catalyzing AI-Enabled Innovation in Drug Development.

Adarsh Subbaswamy, Allison Dunn, Brooke Langevin, Sooyoung Lee, Mathangi Gopalakrishnan, Jogarao V S Gobburu

Abstract read
In one paragraph

Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Adarsh SubbaswamyCenter for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.ORCID 0000-0003-2020-1806
Allison DunnCenter for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.ORCID 0000-0002-0949-0240
Brooke LangevinCenter for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.ORCID 0009-0000-0628-5746
Sooyoung LeeCenter for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.ORCID 0000-0002-4800-4348
Mathangi GopalakrishnanCenter for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.ORCID 0000-0003-2881-9870
Jogarao V S GobburuCenter for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.ORCID 0000-0002-8348-4295

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2015, President Obama announced the Precision Medicine Initiative in his nationally televised State of the Union address. The vision was bold: to enable a new era of medicine through research, technology, and policies that empower patients, researchers, and providers to work together toward the development of individualized care. Now, more than 10 years later, how have the treatments available to patients changed?

Indexed as

Artificial IntelligenceDrug DevelopmentPrecision MedicineHumansUnited Statesartificial intelligencedrug developmentpersonalized medicineprecision medicineregulatory science

Identifiers

PMID42153675
PMCPMC13185207

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.